CD19/BCMA CAR-iNK therapy(Tome Biosciences)

N/A

Report date: 2024/05/30 17:46:54

Base Information

Drug NameCD19/BCMA CAR-iNK therapy(Tome Biosciences)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionNatural killer cell replacementsB-lymphocyte antigen CD19 modulatorsB-cell maturation protein modulators

TargetsB-lymphocyte antigen CD19B-cell maturation protein

Therapy Area/IndicationsAutoimmune DiseasesKidney Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesTome Biosciences Inc

China Registration ClassN/A

Develop Information

Active CompaniesTome Biosciences Inc

Inactive CompaniesN/A

Active IndicationsAutoimmune DiseasesKidney Diseases

Inactive IndicationsN/A

Other Information

ATC CodeN/A